Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions

Abstract

BackgroundAlthough the management of sarcoma is improving, non adherence to clinical practice guidelines (CPGs) remains high, mainly because of the low incidence of the disease and the variety of histological subtypes. Since little is known about the health economics of sarcoma, we undertook a cost-effectiveness analysis (within the CONnective TIssue CAncer NETwork, CONTICANET) comparing costs and outcomes when clinicians adhered to CPGs and when they did not.MethodsPatients studied had a histological diagnosis of sarcoma, were older than 15 years, and had been treated in the Rhône-Alpes region of France (in 2005/2006) or in the Veneto region of Italy (in 2007). Data collected retrospectively for the three years after diagnosis were used to determine relapse free survival and health costs (adopting the hospital's perspective and a microcosting approach). All costs were expressed in euros (€) at their 2009 value. A 4% annual discount rate was applied to both costs and effects. The incremental cost-effectiveness ratio (ICER) was expressed as cost per relapse-free year gained when management was compliant with CPGs compared with when it was not. To capture uncertainty surrounding ICER, a probabilistic sensitivity analysis was performed based on a non-parametric bootstrap method.ResultsA total of 219 patients were included in the study. Compliance with CPGs was observed for 118 patients (54%). Average total costs reached 23,571 euros when treatment was in accordance with CPGs and 27,313 euros when it was not. In relation to relapse-free survival, compliance with CPGs strictly dominates non compliance, i.e. it is both less costly and more effective. Taking uncertainty into account, the probability that compliance with CPGs still strictly dominates was 75%.ConclusionsOur findings should encourage physicians to increase their compliance with CPGs and healthcare administrators to invest in the implementation of CPGs in the management of sarcoma.

International clinical trials setting for rare cancers: organisational and regulatory constraints—the EORTC perspective

“…Their incidence is about 2% [8], and as shown by Ray-Coquard et al [9], more than 40% of histological diagnoses are modified after review. Clinical practice guidelines for their management have been established; however, non-adherence to these guidelines remains high [10]. …”

Advancing towards Better Cooperation for Better Sarcoma Prognoses

“…Moreover, a retrospective analysis of 219 patients with sarcoma treated at specialised centres in France and Italy found that clinicians’ adherence to clinical practice guidelines was cost-effective in terms of total treatment costs and relapse-free survival (both were less costly and more effective) [15]. …”

Les critères de qualité de la prise en charge chirurgicale des sarcomes des tissus mous

“…Dans une étude du Groupe sarcome français [1], près de la moitié des patients atteints d'un sarcome des tissus mous est mal prise en charge sur le plan chirurgical, ce qui expose à des reprises chirurgicales qui auraient pu être évitées, à des surcoûts [2], et surtout des récidives qui peuvent compromettre la vie du patient en particulier dans les localisations tronculaires [3]. La conformité globale aux référentiels n'est malheureusement que de 40 % [4].…”